Dolutegravir (GSK1349572)

Catalog No.S2667

Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Price Stock Quantity  
USD 450 In stock
USD 270 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Dolutegravir (GSK1349572) Chemical Structure

Dolutegravir (GSK1349572) Chemical Structure
Molecular Weight: 419.38

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Dolutegravir (GSK1349572) is available in the following compound libraries:

Product Information

  • Compare Integrase Inhibitors
    Compare Integrase Products
  • Research Area
  • Dolutegravir (GSK1349572) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.
Targets HIV integrase [2]
(Cell-free assay)
IC50 2.7 nM
In vitro S/GSK1349572 shows the potent inhibitory effect on nine clinical isolates from integrase inhibitor-naive HIV-2-infected patients with EC50 ranging from 0.2 nM -1.4 nM. [1] In vitro, S/GSK1349572 inhibits recombinant HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM. Furthermore, S/GSK1349572 potently inhibits HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector with EC50 of 0,51 nM, 0.71 nM and 2.2 nM, respectively. [2] In vitro, S/GSK1349572 exhibits potent activity against five different nonnucleoside reverse transcription inhibitor--resistant or nucleoside reverse transcription inhibitor--resistant viruses with EC50 ranging from 1.3 nM -2.1 nM. Similarly to that against wild-type virus, S/GSK1349572 shows equivalent activity against two protease inhibitor-resistant viruses with EC50 of 0.36 nM and 0.37 nM, respectively. [2]
In vivo
Features A next-generation and two-metal-binding HIV integrase strand transfer inhibitor.

Protocol(Only for Reference)

Kinase Assay:

[2]

In vitro strand transfer assay The inhibitory potencies of S/GSK1349572 and other INIs are measured in a strand transfer assay using recombinant HIV integrase. A complex of integrase and biotinylated preprocessed donor DNA-streptavidin-coated Acintillation proximity assay (SPA) beads is formed by incubating 2 μM purified recombinant integrase with 0.66 μM biotinylated donor DNA-4 mg/mL streptavidin-coated SPA beads in 25 mM sodium morpholinepropanesulfonic acid (MOPS) (pH 7.2), 23 mM NaCl, and 10 mM MgCl2 for 5 minutes at 37 °C. These beads are spun down and preincubated with diluted INIs for 60 minutes at 37 °C. Then a 3H-labeled target DNA substrate is added to give a final concentration of 7 nM substrate, and the strand transfer reaction mixture is incubated at 37 °C for 25 to 45 minutes, which allows for a linear increase in the strand transfer of donor DNA to radiolabeled target DNA. The signal is read using a Wallac MicroBeta scintillation plate reader.

Cell Assay:

[2]

Cell lines MT-4
Concentrations 0 to 10 μM
Incubation Time 4 days or 5 days
Method

MT-4 cells growing exponentially at a density of 500000 or 600000 /mL are infected with HIV-1 strain IIIB at a viral multiplicity of infection of 0.001 or a 50% tissue culture infective dose of 4 to 10. The cells are then aliquoted to 96-well plates in the presence of varying concentrations of S/GSK1349572. After incubation for 4 or 5 days, antiviral activity is determined by a cell viability assay that either measured bioluminescence with a CellTiter-Glo luminescent reagent or measured absorbance at 560 and 690 nm using the yellow tetrazolium MTT reagent [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide].

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Charpentier C, et al. AIDS. 2010, 24(17), 2753-275

[2] Kobayashi M, et al. Antimicrob Agents Chemother. 2011, 55(2), 813-821.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02777229 Recruiting HIV-1 Infection French National Institute for Health and Medical Research  ...more French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Institut de Recherche pour le Developpement July 2016 Phase 3
NCT02831673 Not yet recruiting Infection, Human Immunodeficiency Virus ViiV Healthcare|PPD|GlaxoSmithKline July 2016 Phase 3
NCT02831764 Not yet recruiting Infection, Human Immunodeficiency Virus ViiV Healthcare|PPD|GlaxoSmithKline July 2016 Phase 3
NCT02738931 Completed Infection, Human Immunodeficiency Virus ViiV Healthcare|GlaxoSmithKline May 2016 Phase 1
NCT02771249 Recruiting Healthy Volunteers National Institutes of Health Clinical Center (CC) May 2016 Phase 1

view more

Chemical Information

Download Dolutegravir (GSK1349572) SDF
Molecular Weight (MW) 419.38
Formula

C20H19F2N3O5

CAS No. 1051375-16-6
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms S/GSK1349572
Solubility (25°C) * In vitro DMSO 83 mg/mL warming (197.91 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Integrase Products

  • Cabotegravir (GSK744, GSK1265744)

    Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.

  • Tenofovir Alafenamide (GS-7340)

    Tenofovir Alafenamide (GS-7340) is a prodrug of tenofovir, which is a reverse transcriptase inhibitor, used to treat HIV and Hepatitis B.

  • Elvitegravir (GS-9137, JTK-303)

    Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.

  • Raltegravir (MK-0518)

    Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively.

    Features:The 1st approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor.

  • BMS-707035

    BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.

  • MK-2048

    MK-2048 is a potent inhibitor of integrase (IN) and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively.

  • Maraviroc

    Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively.

  • Tenofovir Disoproxil Fumarate

    Tenofovir Disoproxil Fumarate belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.

  • Zidovudine

    Zidovudine (ZDV) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV.

Recently Viewed Items

Tags: buy Dolutegravir (GSK1349572) | Dolutegravir (GSK1349572) supplier | purchase Dolutegravir (GSK1349572) | Dolutegravir (GSK1349572) cost | Dolutegravir (GSK1349572) manufacturer | order Dolutegravir (GSK1349572) | Dolutegravir (GSK1349572) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us